MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies.
$1.30+3.17%
报价 2026-11-09
市值
$134.2M
EV
$178.7M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -26.1%
$0.68$1.76
筛选结果
pipeline · 2026-11-09Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| MXCTMaxCyte, Inc. | $134.2M | +3.2% | -11.4% | 79.4% | – | – | – | |
| AVRAnteris Technologies Global Corp. | $578.9M | +4.4% | – | 28.2% | – | – | – | |
| PREPrenetics Global Limited | $297.3M | +10.1% | – | 62.6% | – | – | – | |
| PROFProfound Medical Corp. | $268.1M | +1.8% | – | 71.7% | – | – | – | |
| TLSITriSalus Life Sciences, Inc. | $198.3M | -0.9% | +19.9% | 85.8% | – | – | – | |
| ARMPArmata Pharmaceuticals, Inc. | $141.3M | +8.3% | +13.3% | 68.2% | – | – | – | |
| OWLTOwlet, Inc. | $127.4M | +4.6% | +15.4% | 54.7% | – | – | – | |
| CATXPerspective Therapeutics, Inc. | $97.7M | +1.9% | -54.5% | -419.4% | – | – | – | |
| LNSRLENSAR, Inc. | $67.1M | +0.2% | -3.3% | 48% | 6.7x | 2.6x | – | |
| 同行中位数 | – | – | +13.3% | 58.7% | 6.7x | 2.6x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。